INO:NASDAQ

Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.
INO:NASDAQ

Expert Comments:

Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors.
read more >
Charles Duncan, Piper Jaffray & Co. (6/8/17)
"Inovio Pharmaceuticals Inc. announced the clinical hold has been lifted on its VGX-3100 cervical dysplasia program and it will now begin enrolling patients in the Phase III REVEAL studies. . .the late-stage progress in cervical dysplasia also prompts us to take a "glass half full" approach to valuing the deeper pipeline, as we have confidence early-stage efforts can eventually move into later-stage, value-creating trials as well. We are moving to Overweight and taking our PT up to $14. . .we are supportive of this update, as we think it should diversify risk without adding to the time or capital requirements."

Ram Selvaraju, H.C. Wainwright & Co. (6/8/17)
"Inovio Pharmaceuticals Inc. announced that the FDA has removed the clinical hold regarding the company’s Cellectra® 5PSP delivery device, and the company has started the Phase 3 pivotal study of VGX-3100. . .we note that VGX-3100 is the first candidate within the company's extensive pipeline to enter a pivotal study, and is the first immunotherapy and non-surgical treatment for high-grade squamous intraepithelial lesions. In the wake of this update, we reiterate our Buy rating."

Jason McCarthy, Maxim Group (6/8/17)
"Inovio Pharmaceuticals Inc. announced that the clinical hold on the Phase III program evaluating VGX-3100 for the treatment of cervical dysplasia has been lifted and the company will immediately begin enrolling patients. . .while Inovio has continued to advance multiple earlier-stage DNA-based immunotherapies forward, providing incremental catalysts for the stock, our focus has remained on the start of the Phase III program for VGX-3100 in high-grade cervical dysplasia. . .VGX-3100 is the key driver of Inovio. With the clinical hold now lifted, Inovio has transformed into a pivotal company."

Ram Selvaraju, H.C. Wainwright & Co. (6/2/17)
"Inovio Pharmaceuticals Inc. announced the second collaboration study involving the company’s INO-5401 T-cell activating immunotherapy. . .Genentech, a member of Roche Holding AG, will supply Tecentriq to be used in combination with INO-5401 and INO-9012 in an open-label Phase 1b/2 trial in patients with advanced bladder cancer. . .Inovio's immunotherapy may provide a viable option to those who have failed chemotherapy and checkpoint inhibitors. . .we believe both studies with INO-5401 could report results in 2018. In the wake of this update, we reiterate our Buy rating and $13 price target."

Jason McCarthy, Maxim Group (6/1/17)
"Inovio Pharmaceuticals Inc. announced a collaboration with Roche to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer. The P1b/2 study will enroll 80 patients with advanced, unresectable or metastatic bladder cancer (urothelial carcinoma), including many patients that have previously failed checkpoint monotherapy. . .Inovio's DNA-based immunotherapies have demonstrated robust multi-layered immune responses across multiple indications. As such we see Inovio playing a significant role in advancing the utility of checkpoints across larger cancer populations."

A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts.
read more >
Zacks Equity Research (5/26/17)
"Inovio Pharmaceuticals Inc. shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study. . .Inovio’s share price has outperformed the Zacks categorized Medical - Biomedical and Genetics industry in the past one year. . . .94% evaluated participants demonstrated an env specific antibody response. These responses were not observed in any of the participants treated with a placebo. . .the government-sponsored study conducted by Inovio and its collaborators was funded through a $25 million NIAID contract awarded in 2009 with an additional grant of $16 million in 2015 for the development of a HIV vaccine."

Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers.
read more >
Management Q&A: View From the Top
J. Joseph Kim
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses.
read more >

More Expert Comments

Experts Following This Company

Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Nick Hodge, Founder and president of the Outsider Club – Outsider Club
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.